Breaking News
Get 50% Off 0
💎 Bargain Hunter: Undervalued stocks with massive upside potential
Get the list
Close

Sichuan Kelun Biotech (6990)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
419.80 -13.20    -3.05%
08:59:59 - Closed. Currency in HKD
Type:  Equity
Market:  Hong Kong
ISIN:  CNE1000062J1 
  • Volume: 952,375
  • Bid/Ask: 418.60 / 419.80
  • Day's Range: 410.60 - 436.40
Sichuan Kelun Biotech 419.80 -13.20 -3.05%

Sichuan Kelun Biotech Company Profile

 
Get an in-depth profile of Sichuan Kelun Biotech, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

1837

Equity Type

ORD

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally. Its product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

Contact Information

Address No. 666 Xinhua Avenue Chengdu Cross-Strait
Science and Technology Industry Development Park Wenjiang District Chengdu,
China
Phone -
Fax -

Top Executives

Name Age Since Title
Sichuan Liu 41 2016 Non-Executive Director
Yuedong Li 48 2023 Independent Non-Executive Director
Gexin Liu 73 2016 Non-Executive Chairman of the Board
Hao Feng 45 2021 Non-Executive Director
Junyou Ge 53 2021 President, CEO, COO, GM & Executive Director
Xuebo Zeng 39 2022 Non-Executive Director
Qiang Zheng 63 2023 Independent Non-Executive Director
Hongmei Song 41 2021 Supervisor
Qiuyan Yang 39 2022 Supervisor
Jinping Jin 52 2023 Independent Non-Executive Director
Degui Lai 54 2021 Non-Executive Director
Wenwei Tu 57 2023 Independent Non-Executive Director
Yan Qing 40 2022 Supervisor
Yihong Liao 44 2022 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

6990 Comments

Write your thoughts about Sichuan Kelun Biotech
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email